Cytomegalovirus infection induces a stem cell phenotype in human primary glioblastoma cells: Prognostic significance and biological impact

Cell Death and Differentiation

Volumn 23, Issue 2, 2016, Pages 261-269

  Fornara, O ^a,b   Bartek, J ^a,b,c,d,e   Rahbar, A ^a   Odeberg, J ^a   Khan, Z ^a   Peredo, I ^a   Hamerlik, P ^d   Stragliotto, G ^b   Landazuri N ^a   Soderberg Naucler C ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c University of Copenhagen   (Denmark)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; GAMMA SECRETASE INHIBITOR; GANCICLOVIR; IMMEDIATE EARLY PROTEIN; NESTIN; NOTCH1 RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTE; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GLIOBLASTOMA CELL LINE; GLIOMA STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; NERVE CELL; PHENOTYPE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UPREGULATION; BRAIN TUMOR; CANCER STEM CELL; CELL TRANSFORMATION; CYTOMEGALOVIRUS; DISEASE FREE SURVIVAL; GLIOBLASTOMA; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTICELLULAR SPHEROID; PATHOLOGY; PHYSIOLOGY; PRIMARY CELL CULTURE; VIROLOGY;

ADULT; AGED; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CYTOMEGALOVIRUS; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PHENOTYPE; PRIMARY CELL CULTURE; PROGNOSIS; SPHEROIDS, CELLULAR;

EID: 84954362800     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.91     Document Type: Article

References (34)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
2. Lima FR, Kahn SA, Soletti RC, Biasoli D, Alves T, da Fonseca AC et al. Glioblastoma: therapeutic challenges, what lies ahead. Biochim Biophys Acta 2012; 1826: 338-349.
3. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
4. Cheng JX, Liu BL, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev 2009; 35: 403-408.
5. Ardebili SY, Zajc I, Gole B, Campos B, Herold-Mende C, Drmota S et al. CD133/prominin1 is prognostic for GBM patient's survival, but inversely correlated with cysteine cathepsins' expression in glioblastoma derived spheroids. Radiol Oncol 2011; 45: 102-115.
6. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008; 14: 123-129.
7. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-4015.
8. Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 2008; 62: 505-514; discussion 514-505.
9. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008; 122: 761-768.
10. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010; 17: 362-375.
11. Ishiwata T, Teduka K, Yamamoto T, Kawahara K, Matsuda Y, Naito Z. Neuroepithelial stem cell marker nestin regulates the migration, invasion and growth of human gliomas. Oncol Rep 2011; 26: 91-99.
12. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010; 16: 3141-3152.
13. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
14. Stopschinski BE, Beier CP, Beier D. Glioblastoma cancer stem cells-from concept to clinical application. Cancer Lett 2013; 338: 32-40.
15. Florio T, Barbieri F. The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells. Drug Disc Today 2012; 17: 1103-1110.
16. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002; 62: 3347-3350.
17. Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med 2013; 369: 985-986.
18. Rahbar A, Orrego A, Peredo I, Dzabic M, Wolmer-Solberg N, Straat K et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol 2013; 57: 36-42.
19. Sinclair J. Human cytomegalovirus: Latency and reactivation in the myeloid lineage. J Clin Virol 2008; 41: 180-185.
20. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91: 119-126.
21. Perez-Garcia A, Carrion-Navarro J, Bosch-Fortea M, Lazaro-Ibanez E, Prat-Acin R, Ayuso-Sacido A. Genomic instability of surgical sample and cancer-initiating cell lines from human glioblastoma. Front Biosci 2012; 17: 1469-1479.
22. Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Hlobilkova A, Laursen H et al. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas. Oncogene 2010; 29: 5095-5102.
23. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
24. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 2014; 344: 1396-1401.
25. Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G. CD133 is essential for glioblastoma stem cell maintenance. Stem Cell 2013; 31: 857-869.
26. Odeberg J, Wolmer N, Falci S, Westgren M, Seiger A, Soderberg-Naucler C. Human cytomegalovirus inhibits neuronal differentiation and induces apoptosis in human neural precursor cells. J Virol 2006; 80: 8929-8939.
27. Hu J, Ho AL, Yuan L, Hu B, Hua S, Hwang SS et al. From the Cover: Neutralization of terminal differentiation in gliomagenesis. Proc Natl Acad Sci USA 2013; 110: 14520-14527.
28. Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF. Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples. J Virol 2012; 86: 854-864.
29. Bhattacharjee B, Renzette N, Kowalik TF. Genetic analysis of cytomegalovirus in malignant gliomas. J Virol 2012; 86: 6815-6824.
30. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-oncol 2008; 10: 10-18.
31. Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E et al. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res 2013; 19: 6473-6483.
32. Stern-Ginossar N, Weisburd B, Michalski A, Le VT, Hein MY, Huang SX et al. Decoding human cytomegalovirus. Science 2012; 338: 1088-1093.
33. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cell 2010; 28: 5-16.
34. Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ 2014; 21: 258-269.